UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Reducing the immunogenicity of protein therapeutics

Current drug targets, 2009-02, Vol.10 (2), p.131-139

Onda, Masanori

2009

Volltextzugriff (PDF)

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

Proceedings of the National Academy of Sciences - PNAS, 2012-07, Vol.109 (29), p.11782-11787

2012

Volltextzugriff (PDF)

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

Proceedings of the National Academy of Sciences - PNAS, 2014-06, Vol.111 (23), p.8571-8576

2014

Volltextzugriff (PDF)

Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine

British journal of cancer, 2022-03, Vol.126 (5), p.754-763

2022

Volltextzugriff (PDF)

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes

Proceedings of the National Academy of Sciences - PNAS, 2011-04, Vol.108 (14), p.5742-5747

2011

Volltextzugriff (PDF)

immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes

Proceedings of the National Academy of Sciences - PNAS, 2008-08, Vol.105 (32), p.11311-11316

2008

Volltextzugriff (PDF)

A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity

Molecular cancer therapeutics, 2013-01, Vol.12 (1), p.48-57

2013

Volltextzugriff (PDF)

Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer

Clinical cancer research, 2006-01, Vol.12 (2), p.447-453

2006

Volltextzugriff (PDF)

Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A

Toxins, 2016-07, Vol.8 (8), p.217-217

2016

Volltextzugriff (PDF)

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors

Molecular cancer, 2006-10, Vol.5 (1), p.50-50, Article 50

2006

Volltextzugriff (PDF)

Mesothelin Expression in Human Lung Cancer

Clinical cancer research, 2007-03, Vol.13 (5), p.1571-1575

2007

Volltextzugriff (PDF)

Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy

Molecular oncology, 2016-10, Vol.10 (8), p.1317-1329

2016

Volltextzugriff (PDF)

Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity

Proceedings of the National Academy of Sciences - PNAS, 2019-03, Vol.116 (10), p.4575-4582

2019

Volltextzugriff (PDF)

Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients

Clinical cancer research, 2005-05, Vol.11 (10), p.3814-3820

2005

Volltextzugriff (PDF)

Immunogenicity of therapeutic recombinant immunotoxins

Immunological reviews, 2016-03, Vol.270 (1), p.152-164

2016

Volltextzugriff (PDF)

Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma

Clinical cancer research, 2006-07, Vol.12 (14), p.4225-4231

2006

Volltextzugriff (PDF)

Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia

Clinical cancer research, 2006-04, Vol.12 (8), p.2434-2441

2006

Volltextzugriff (PDF)

In Vitro Antibody Evolution Targeting Germline Hot Spots to Increase Activity of an Anti-CD22 Immunotoxin

The Journal of biological chemistry, 2005-01, Vol.280 (1), p.607-617

2005

Volltextzugriff (PDF)

HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity

Clinical cancer research, 2005-02, Vol.11 (4), p.1545-1550

2005

Volltextzugriff (PDF)

Site-Specific Chemical Modification with Polyethylene Glycol of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) Improves Antitumor Activity and Reduces Animal Toxicity and Immunogenicity

Proceedings of the National Academy of Sciences - PNAS, 2000-07, Vol.97 (15), p.8548-8553

2000

Volltextzugriff (PDF)

Abstract 4510: RG7787 - a novel de-immunized PE based fusion protein for therapy of mesothelin-positive solid tumors

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4510-4510

2014

Volltextzugriff (PDF)

New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA

Clinical cancer research, 2005-08, Vol.11 (16), p.5840-5846

2005

Volltextzugriff (PDF)

Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers

Clinical chemistry and laboratory medicine, 2012-04, Vol.50 (4), p.721-725

2012

Volltextzugriff (PDF)

The improvement of an anti-CD22 immunotoxin: Conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan

mAbs, 2011-09, Vol.3 (5), p.479-486

2011

Volltextzugriff (PDF)

Tob2, a novel anti-proliferative Tob/BTG1 family member, associates with a component of the CCR4 transcriptional regulatory complex capable of binding cyclin-dependent kinases

Oncogene, 1999-12, Vol.18 (52), p.7432-7441

1999

Volltextzugriff (PDF)

1 – 25 von 145

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(115)
Mit Volltextzugriff
(129)

Publikationsform

Sprache

Englisch
(137)
Japanisch
(45)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(98)
Life Sciences & Biomedicine
(64)
Humans
(59)
Animals
(42)
Mice
(37)
Female
(33)
Oncology
(31)
Biological And Medical Sciences
(27)
Medical Sciences
(23)
Pseudomonas Aeruginosa Exotoxin A
(22)
Physical Sciences
(20)
Pseudomonas
(20)
Cell Line, Tumor
(19)
Pharmacology. Drug Treatments
(17)
Male
(16)
Antineoplastic Agents
(14)
Science & Technology - Other Topics
(14)
Tumors
(14)
Immunotherapy
(13)
Immunotoxins - Genetics
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Reducing the immunogenicity of protein therapeutics

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes

immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes

A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity

Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer

Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors

Mesothelin Expression in Human Lung Cancer

Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy

Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity

Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients

Immunogenicity of therapeutic recombinant immunotoxins

Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma

Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia

In Vitro Antibody Evolution Targeting Germline Hot Spots to Increase Activity of an Anti-CD22 Immunotoxin

HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity

Site-Specific Chemical Modification with Polyethylene Glycol of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) Improves Antitumor Activity and Reduces Animal Toxicity and Immunogenicity

Abstract 4510: RG7787 - a novel de-immunized PE based fusion protein for therapy of mesothelin-positive solid tumors

New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA

Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers

The improvement of an anti-CD22 immunotoxin: Conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan

Tob2, a novel anti-proliferative Tob/BTG1 family member, associates with a component of the CCR4 transcriptional regulatory complex capable of binding cyclin-dependent kinases

Suchergebnisse filtern